Get the Stockscreener App
2.43
5.81%
-0.15
After Hours:
2.42
-0.01
-0.41%
Maravai Lifesciences Holdings Inc stock is traded at $2.43, with a volume of 5.28M.
It is down -5.81% in the last 24 hours and down -40.44% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
See More
Previous Close:
$2.58
Open:
$2.56
24h Volume:
5.28M
Relative Volume:
1.97
Market Cap:
$344.68M
Revenue:
$288.95M
Net Income/Loss:
$-119.03M
P/E Ratio:
-2.6985
EPS:
-0.9005
Net Cash Flow:
$60.67M
1W Performance:
-6.90%
1M Performance:
-40.44%
6M Performance:
-72.51%
1Y Performance:
-69.70%
1-Day Range:
$2.25
$2.67
1-Week Range:
$2.25
$2.71
52-Week Range:
$2.25
$11.55
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
2.43 | 344.68M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-19-24 | Initiated | Guggenheim | Neutral |
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-10-24 | Initiated | Craig Hallum | Buy |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-09-23 | Downgrade | Goldman | Buy → Neutral |
| Jan-05-23 | Downgrade | UBS | Buy → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Initiated | Credit Suisse | Outperform |
| Dec-15-20 | Initiated | Goldman | Buy |
| Dec-15-20 | Initiated | Jefferies | Buy |
| Dec-15-20 | Initiated | Robert W. Baird | Outperform |
| Dec-15-20 | Initiated | Stifel | Buy |
| Dec-15-20 | Initiated | William Blair | Outperform |
| Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
MRVI Investors Have Opportunity to Lead Maravai Lifesciences Holdings, Inc. Securities Fraud Lawsuit - PR Newswire
Kirby McInerney LLP Reminds Maravai Lifesciences Holdings (MRVI) Investors of Securities Class Action - TradingView
MRVI INVESTOR NOTICE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Class Action Reminder for MRVI Investors: Kessler Topaz - GlobeNewswire
MRVI Investors Reminded of Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences - GlobeNewswire
Maravai Lifesciences stock hits 52-week low at $2.33 By Investing.com - Investing.com UK
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Maravai LifeSciences Holdings, Inc. (MRVI) Shareholders - ACCESS Newswire
MRVI STOCK NEWS: Maravai LifeSciences Holdings, Inc. Shareholders with Large Losses Should Contact Shareholder Rights Law Firm Robbins LLP for Information About the MRVI Securities Fraud Class Action - PR Newswire
Maravai LifeSciences Reports Q4 EPS of $(0.18) and Revenue of $5 - GuruFocus.com
Maravai LifeSciences Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MARAVAI LIFESCIENCES HOLDINGS, INC. SEC 10-K Report - TradingView
Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
PureCycle Lands Major $33M Backing to Scale Revolutionary Recycling Technology - StockTitan
Maravai LifeSciences Holdings, Inc. Class Action: Levi & - GlobeNewswire
Deadline Alert: Maravai LifeSciences Holdings, Inc. (MRVI) - GlobeNewswire
Deadline Alert: Maravai LifeSciences Holdings, Inc. (MRVI) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
Maravai LifeSciences Holdings, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationMRVI - PR Newswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Maravai - GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Maravai Lifesciences Holdings, Inc. Investors to - Bluefield Daily Telegraph
MRVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Investors who lost money on Maravai LifeSciences Holdings, - GlobeNewswire
Investors who lost money on Maravai LifeSciences Holdings, Inc.(MRVI) should contact The Gross Law Firm about pending Class Action - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holidngs, Inc. of Class Action Lawsuit and Upcoming DeadlinesMRVI - PR Newswire
Maravai LifeSciences Holdings, Inc. (MRVI) Faces Securities Class Action Lawsuit - PR Newswire
Maravai LifeSciences Holdings, Inc. (MRVI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Maravai LifeSciences Holdings, Inc. (MRVI) Faces Securities - GlobeNewswire
Shareholders that lost money on Maravai LifeSciences Holdings, Inc.(MRVI) should contact The Gross Law Firm about pending Class ActionMRVI - PR Newswire
MRVI Shareholders Have Opportunity to Lead the Maravai LifeSciences Holdings, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsMRVI - The Malaysian Reserve
MRVI Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. (MRVI) Investors that a Securities Fraud Class Action Lawsuit Has Been Filed - PR Newswire
Shareholders that lost money on Maravai LifeSciences Holdings, Inc.(MRVI) should contact Levi & Korsinsky about pending Class ActionMRVI - ACCESS Newswire
Levi & Korsinsky Notifies Maravai LifeSciences Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRVI - ACCESS Newswire
MRVI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Maravai LifeSciences Holdings, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Maravai LifeSciences Faces Securities Class Action Lawsuit Following Financial Reporting Issues - Apna Kal
Maravai LifeSciences Faces Securities Class Action Lawsuit Over Alleged Financial Misconduct - Apna Kal
Kessler Topaz Meltzer & Check, LLP Reminds Maravai - GlobeNewswire
MRVI INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Maravai - GlobeNewswire
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Class Action Filed Against Maravai LifeSciences Holdings, - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences - The Malaysian Reserve
The Gross Law Firm Notifies Maravai LifeSciences Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRVI - PR Newswire
Marvai LifeSciences Holdings, Inc. Shareholders with Large Losses are Encouraged to Contact Robbins LLP for Information About Leading the Securities Fraud Class Action Lawsuit Against MRVI - GlobeNewswire
Marvai LifeSciences Holdings, Inc. Shareholders with Large Losses are Encouraged to Contact ... - Bluefield Daily Telegraph
Marvai LifeSciences Holdings, Inc. Shareholders with Large - GlobeNewswire
MRVI INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Lowey Dannenberg Notifies Maravai LifeSciences Holdings, - GlobeNewswire
Levi & Korsinsky Notifies Shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on Maravai LifeSciences Holdings, Inc.(MRVI) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Reminds Maravai LifeSciences Holdings, Inc. Inv - GuruFocus.com
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):